You are here: Industry Insights > Immuno-Oncology

News List

F-Prime, Atlas lead cancer startup Akrevia to $30M A round fiercebiotech
September 28, 2018
Akrevia Therapeutics has raised a $30 million series A round led by F-Prime Capital Partners and Atlas Venture.
Boehringer buys oncolytic virus startup ViraTherapeutics fiercebiotech
September 14, 2018
The potential for oncolytic viruses to broaden the effectiveness of checkpoint inhibitors has returned the modality to the spotlight.
This gene mutation is key to glioblastoma’s ‘immortality’ and could point to drug targets fiercebiotech
September 11, 2018
Glioblastoma, the brain cancer that took the life of Sen. John McCain, has proven especially difficult to target with drugs.
Allogene raises another $120M for off-the-shelf CAR-T programs fiercebiotech
September 07, 2018
Round adds to $300M in startup funding for Allogene (Pixabay/Quincemedia)
GIC receives govt funding for immuno-oncology project biospectrumasia
August 23, 2018
The company is currently conducting studies on a family of compounds targeted towards the Adenosine 2a receptor.
DotBio successfully raises $2.3 M in seed financing biospectrumasia
August 08, 2018
Newly formed company raises US$2.3 million seed financing led by HeungKong Group to complete validation studies of optimized, humanized domain antibodies and explore broad applicability of DotBody technology
I-Mab Biopharma, ABL Bio collaborate for innovative bispecific Abs biospectrumasia
July 30, 2018
Under the terms of the agreement, ABL Bio will pay $2.5 million in upfront payment.
Merck's Keytruda shores up head and neck case with first-line trial win biospectrumasia
July 26, 2018
Merck’s Keytruda may just be on its way to earlier use in head and neck cancer, an area where it once faced some questions.
ProBioGen and Pionyr initiate 2nd immuno-oncology contract development and manufacturing project cphi-online
July 25, 2018
Parallel cell line development and analysis will allow for optimal cell line selection while compressing the development timeline.
Bristol-Myers Squibb commercial chief Gordon jumps ship ahead of key Opdivo launch fiercepharma
July 24, 2018
Bristol-Myers Squibb is locked in some pretty big marketing battles—but it’ll have to soldier on without its commercial leader.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page